Zoledronic Acid Treatment of Spontaneous Osteonecrosis of the Knee

Novartis

Status and phase: Withdrawn; Phase 2

Conditions: Osteonecrosis

Treatments: Drug: Zoledronic acid

Study type: Interventional

Funder types: Industry

Identifiers

NCT00477217

CZOL446HAU21

Details and patient eligibility

About

This study will assess the safety and efficacy of zoledronic acid in patients presenting with spontaneous osteonecrosis of the knee.

Sex: All

Ages: 40 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults 40-85 years of age
• Diagnosis of painful osteonecrosis of the knee within the last month.

Exclusion criteria

• Intravenous (iv) bisphosphonates within the last 2 years.
• Abnormal thyroid, kidney or liver function.
• Abnormal blood calcium or alkaline phosphatase levels.

Other protocol-defined inclusion/exclusion criteria may apply

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

1

Other group

Treatment:

Drug: Zoledronic acid